Thrombospondin1 antagonists and diabetic nephropathy

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Despite increased glycemic control and use of renin-angiotensin system inhibitors, diabetic nephropathy remains a leading cause of end stage renal disease. The fibrogenic cytokine, transforming growth factor-¿ (TGF-¿), is a key molecular factor in the pathogenesis of diabetic nephropathy. The expression of TGF-¿ and its activity are increased in diabetes. TGF-¿ is expressed as a biologically latent molecule that must be converted to its active form in order to induce fibrogenic effects. This activation step represents a major point of regulation of TGF-¿ bioactivity. We identified thrombospondin 1 (TSP1) as the molecular regulator of TGF-¿ activation in diabetes. TSP1 protein expression is increased by mediators of diabetic nephropathy such as glucose and angiotensin II. In vitro studies and a rat model of STZ-induced diabetes with hypertension showed that antagonism of TSP1-dependent TGF-¿ activation by a four amino acid peptide (LSKL) blocked glucose and angiotensin II stimulation of TGF-¿ activity, extracellular matrix production, and prevented and reversed myocardial fibrosis. The LSKL peptide when administered by intraperitoneal injection is an effective antagonist of TGF-¿ -dependent fibrosis in this model and in other non-diabetic models of renal and hepatic fibrosis. The LSKL peptide represents an effective therapeutic strategy for treatment of diabetic nephropathy: this peptide has the unique advantage of selectively inhibiting only the pathogenic increases in TGF-¿ activity due to TSP1-mediated activation. This distinguishes LSKL from other strategies for inhibiting TGF-¿ action, which do not discriminate between homeostatic levels and pathologic excesses of TGF-¿ activity. In these studies, we will test the hypothesis that administration of the LSKL peptide improves renal function and attenuates renal fibrosis by blocking activation of TGF- ¿ in a newly developed genetic mouse model (129/SvEv Ins2 Akita) of type 1 diabetes, which has significant proteinuria and mesangial sclerosis. In Specific Aim 1, mice will receive thrice weekly i.p. injections of LSKL or control (LSAL) peptide over a 15 week period and renal function, morphology, and TGF-¿ signaling will be evaluated. Specific Aim 2 will determine whether a combined therapeutic approach that targets both the angiotensin II type 1 receptor and TSP1 has increased benefit. Importantly, this proposal will address whether homeostatic functions of TGF-¿ are compromised by antagonism of TSP1-dependent activation. Specific Aim 3 will address whether blockade of TSP1-activated TGF-¿ has deleterious effects on homeostatic functions of TGF-¿ with respect to systemic histopathology, tumor incidence, immune cell profile, and dermal wound healing. These studies will help establish the utility of this peptide antagonist of TSP1-dependent TGF-¿ activation as a novel therapeutic for diabetic nephropathy.